The efficacy and safety of anti-CD20 antibody for the treatment of B-ALL: a systematic review and meta-analysis
Xiaomei Zhou, Jiaxi Yang, Jing Fan, Xupai Zhang, Xiao Wang, Hai Yi · 2025
Read The efficacy and safety of anti-CD20 antibody for the treatment of B-ALL: a systematic review and meta-analysis by Xiaomei Zhou, Jiaxi Yang, Jing Fan, Xupai Zhang, Xiao Wang, Hai Yi (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12717365.txt.
Description
Xiaomei Zhou and five co-authors pool trial results on anti-CD20 antibodies for B-cell acute lymphoblastic leukemia. These antibodies hunt the CD20 marker on malignant B cells. Several trials had tested them, but no one had compared the whole field's benefit and safety in one place.
Their 2025 review searched five databases for trials up to November 2024, covering rituximab, obinutuzumab, and ofatumumab. Eight studies with 1,330 patients qualified, two of them randomized trials. Pooling showed antibody treatment improved overall survival, with odds near 1.89 times the control's. Freedom from disease events also improved, at about 1.68 times. Quality checks used standard risk-of-bias tools. The authors aim to guide doctors choosing among these antibodies.
Catalog record
| CREATOR | Xiaomei Zhou, Jiaxi Yang, Jing Fan, Xupai Zhang, Xiao Wang, Hai Yi |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 33 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |